-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies Maintains Buy on ImmunityBio, Raises Price Target to $14

Benzinga·10/15/2026 16:41:20
語音播報
Jefferies analyst Kelly Shi maintains ImmunityBio (NASDAQ:IBRX) with a Buy and raises the price target from $12 to $14.